National Lipid Day, observed on 10 May every year creates awareness of dyslipidaemia, says GlobalData, a leading data and analytics company.

Dr Shireen Mohammad, Cardiovascular & Metabolic Disorders Analyst at GlobalData, comments: “An unmet need in the dyslipidemia space is patient education and National Lipid Day is a great way to raise awareness for this disease and its risk factors to allow early detection and management, which can help improve outcomes and reduce the burden of cardiovascular diseases associated with dyslipidemia.”

It is important to note that dyslipidemia can often be managed through lifestyle modifications, such as adopting a healthy diet, engaging in regular physical activity, maintaining a healthy weight, and, if necessary, taking medication prescribed by a healthcare professional. Regular monitoring of lipid levels and working closely with a healthcare provider are essential to reduce the risks associated with dyslipidemia.

The standard of care for dyslipidemia is statins, with Lipitor (atorvastatin) annual global sales in 2022 reaching $1.7 billion, despite the drug’s patent expiration in 2016. More pipeline drugs for dyslipidemia are expected to be launched within the next 10 years, forecasts GlobalData.

Dr Mohammad concludes: “Dyslipidemia does not often present noticeable symptoms; therefore, individuals may be unaware of their condition until they experience a cardiovascular event. Hence, by promoting awareness there is hope that this will increase the number of individuals who undergo regular lipid profile screening. This will allow for the early detection of dyslipidemia and therefore better management of lipid levels, reducing the risk of cardiovascular diseases.”